WVE Strangle Strategy

WVE (Wave Life Sciences Ltd.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

WVE (Wave Life Sciences Ltd.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.12B, a beta of -1.33 versus the broader market, a 52-week range of 5.02-21.73, average daily share volume of 4.0M, a public-listing history dating back to 2015, approximately 317 full-time employees. These structural characteristics shape how WVE stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of -1.33 indicates WVE has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a strangle on WVE?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current WVE snapshot

As of June 30, 2026, spot at $5.79, ATM IV 297.70%, IV rank 89.48%, expected move 85.35%. The strangle on WVE below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.

Why this strangle structure on WVE specifically: WVE IV at 297.70% is rich versus its 1-year range, which makes a premium-buying WVE strangle relatively expensive in absolute-cost terms, with a market-implied 1-standard-deviation move of approximately 85.35% (roughly $4.94 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated WVE expiries trade a higher absolute premium for lower per-day decay. Position sizing on WVE should anchor to the underlying notional of $5.79 per share and to the trader's directional view on WVE stock.

WVE strangle setup

The WVE strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With WVE near $5.79, the first option leg uses a $6.08 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed WVE chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 WVE shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$6.08	N/A
Buy 1	Put	$5.50	N/A

WVE strangle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

WVE strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on WVE. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on WVE

Strangles on WVE are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the WVE chain.

WVE thesis for this strangle

The market-implied 1-standard-deviation range for WVE extends from approximately $0.85 on the downside to $10.73 on the upside. A WVE long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current WVE IV rank near 89.48% sits in the upper third of its 1-year distribution, which historically reverts; this raises the bar for premium-buying structures and lowers it for premium-selling structures on WVE at 297.70%. As a Healthcare name, WVE options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to WVE-specific events.

WVE strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. WVE positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move WVE alongside the broader basket even when WVE-specific fundamentals are unchanged. Always rebuild the position from current WVE chain quotes before placing a trade.

Frequently asked questions

What is a strangle on WVE?: A strangle on WVE is the strangle strategy applied to WVE (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With WVE stock trading near $5.79, the strikes shown on this page are snapped to the nearest listed WVE chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are WVE strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the WVE strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 297.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a WVE strangle?: The breakeven for the WVE strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current WVE market-implied 1-standard-deviation expected move is approximately 85.35%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on WVE?: Strangles on WVE are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the WVE chain.
How does current WVE implied volatility affect this strangle?: WVE ATM IV is at 297.70% with IV rank near 89.48%, which is elevated relative to its 1-year range. Premium-selling structures (covered call, cash-secured put, iron condor) generally look more attractive when IV rank is high; premium-buying structures (long call, long put, debit spreads) are more expensive in that regime.